Company profile: Aquapharm
1.1 - Company Overview
Company description
- Provider of drug discovery products based on the chemical diversity of marine micro-organisms, including novel pharmaceutical compounds and antibiotics for Gram negative and Gram positive infections, bio-manufactured nutraceuticals, personal care ingredients, and industrial biocatalysts. Maintains a proprietary library of over 7,000 marine micro-organisms and uses SeaRch™ technology to screen and induce production of biologically active compounds.
Products and services
- Pharmaceuticals: Develops marine-derived antibiotics engineered from the chemical diversity of marine microorganisms to treat bacterial infections, targeting both Gram-negative and Gram-positive pathogens for novel therapeutic products
- SeaRch™ Technology: Screening-based platform that screens and induces production of biologically active compounds from marine micro-organisms, enabling discovery of new drug candidates and bioactive products
- Microbial Library: Proprietary repository of over 7,000 marine micro-organisms curated for research and product development, supplying access to chemical diversity for novel pharmaceuticals and other bioactive products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aquapharm
Sequella
HQ: United States
Website
- Description: Provider of biopharmaceutical products for diagnosing and treating epidemic infectious diseases, including SQ109 (Phase 2 for multidrug-resistant pulmonary tuberculosis), Sutezolid (oxazolidinone in clinical development for tuberculosis), SQ609 (preclinical for tuberculosis), SQ641 (preclinical for C. difficile and nontuberculous mycobacteria), B-SMART rapid TB susceptibility tests, and small-molecule and natural product drug discovery programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequella company profile →
Stat-Sure Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic testing specializing in HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Sure Diagnostics company profile →
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Cavidi
HQ: Sweden
Website
- Description: Provider of HIV viral load monitoring diagnostics and BOLD-based immunoassay signal amplification solutions, including Exazym reagent kits for attomole-level biomarker detection (up to 100x amplification), ClickChem conjugation, polymerase reaction and biotin detection kits, plus research services and collaborations on low-abundance biomarker discovery and immunoassay development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cavidi company profile →
Now Diagnostics
HQ: United States
Website
- Description: Provider of rapid, single-drop-of-blood diagnostic tests delivering results within minutes, including ADEXUSDx assays for COVID-19 antibodies, hCG for early pregnancy, syphilis antibodies, elevated acetaminophen, H-FABP for myocardial damage, and methanol detection in blood, plasma, or serum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Now Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aquapharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aquapharm
2.2 - Growth funds investing in similar companies to Aquapharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aquapharm
4.2 - Public trading comparable groups for Aquapharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →